Voiding Dysfunction

Analysis of the Treatment of Two Types of Acute Urinary Retention

Kwangsu Park, Sang Hoon Kim, Sun Gook Ahn, Seung-Ju Lee, U-Syn Ha, Jun Sung Koh, Yong-Seok Lee, Chang Hee Han, Su Yeon Cho, Hyun Woo Kim

Department of Urology, The Catholic University of Korea College of Medicine, Seoul, Korea

Purpose: This study analyzed the type of acute urinary retention (AUR) and evaluated the treatments used, including trial without catheter (TWOC).

Materials and Methods: This study was based on 299 patients who were treated for AUR from January 2007 to August 2009. The patients were classified into the spontaneous AUR group (group S) and the precipitated AUR group (group P), in which AUR was consecutive to triggering events. The treatment modalities including TWOC, the success rate of TWOC, age, prostate-specific antigen (PSA) levels, the volume of the prostate, and the drained volume at catheterization were analyzed in each group.

Results: Of 299 men with AUR, 160 (54%) had spontaneous AUR and 139 (46%) had precipitated AUR. Compared with group P, patients in group S were more likely to be treated by surgery, either immediately (16.9% vs. 3.6%, p < 0.05) or after prolonged catheterization (42.2% vs. 29.1%, p < 0.05). The success rate of TWOC was lower in men of older ages (≥ 70 years) and in those with enlarged prostates (≥ 50 ml), higher PSA levels (≥ 3 ng/ml), and a large drained volume at catheterization (≥ 1,000 ml).

Conclusions: In this group of AUR patients, there were slightly more patients with spontaneous AUR (54%) than with precipitated AUR (46%). The success rate of TWOC was more than 70% regardless of the type of AUR. Although TWOC is recommended primarily in the treatment of AUR, early surgical intervention should be considered if the patient has an enlarged prostate (≥ 50 ml) or a large drained volume at catheterization (≥ 1,000 ml).

Key Words: Prostatic hyperplasia; Urinary catheterization; Urinary retention

INTRODUCTION

Acute urinary retention (AUR) is a common urological emergency in men and is defined as a sudden and painful inability to pass urine voluntarily [1]. It is estimated that 10% of men in their 70s and a third of men in their 80s will experience AUR within the next 5 years [2]. As a primary treatment of AUR caused by benign prostate hyperplasia (BPH), early transurethral prostatectomy (TUR-P) has been frequently performed because it is known to bring about prominent improvement in lower urinary tract symptoms (LUTS) [3]. However, one should not overlook the complications and risks of TUR-P, which can be problems on their own [4]. Murray et al. [5] reported that 23% of study subjects did not require prostatectomy as the result of a urodynamic study performed in patients with AUR. In another study, Pickard et al. [6] reported that about 9.2% of patients who had undergone TUR-P could not perform self-voiding after the surgery so that urethral catheterization and clean intermittent catheterization had to be conducted. Of these patients, 0.9% had to undergo permanent urethral catheterization. Pickard et al. [6] also reported that prostatectomy in patients with a history of AUR had a large risk of postoperative complications.

Management of AUR consists of immediate bladder decompression by catheterization, which is usually followed by BPH-related surgery [7]. Surgical intervention in the presence of a urinary catheter can also lead to an increased
risk of sepsis, which potentially contributes to the observed increase in operative morbidity, especially in older patients [8,9]. These findings led to the increasing use of trial without catheter (TWOC) [7]. Recently, TWOC, which is a therapeutic method to induce self-voiding after a certain period of urethral catheterization, is being attempted in many patients with AUR. However, there is no consensus on the optimal management of AUR in terms of type and duration of catheterization or postcatheterization management. Therefore, this study analyzed the type of AUR and evaluated the treatment methods of AUR.

**MATERIALS AND METHODS**

1. **Patients**
This study was based on the records of all patients who visited The Catholic University of Korea, Catholic Medical Center Hospitals for AUR from January 2007 to August 2009. Patients who had a first episode of AUR and could be followed up for at least 4 weeks were selected for inclusion in the study. Patients who had any previous surgery of the lower urinary tract or AUR secondary to a specific cause such as a urethral stricture or urethral stone were excluded.

2. **Study design**
The patients were classified into the spontaneous AUR group (group S), which had no triggering events, and the precipitated AUR group (group P), in which AUR was consecutive to triggering events.

We defined an immediate surgery as surgery performed without removal of a catheter and an elective surgery as surgery performed after successful initial TWOC. The success rate of TWOC was defined as the percentage of patients who could void successfully after an initial TWOC.

We analyzed the patients’ clinical characteristics and the cause of AUR and its management (TWOC, immediate surgery, elective surgery, and indwelling catheter). We assessed the success rate of TWOC in each group and the predictors of success of TWOC, including age, volume of the prostate, serum prostate-specific antigen (PSA) level, drained volume at catheterization, duration of catheterization, and type of AUR.

Statistical comparisons were made by using Student’s t-test. A p-value < 0.05 were considered statistically significant.

**RESULTS**

1. **Demographic characteristics of the subjects**
As shown in Table 1, age and PSA did not differ significantly between the groups (73.00±10.02 years vs. 72.00±9.80 years and 6.27±7.83 ng/ml vs. 5.32±6.13 ng/ml, respectively, p >0.05). Compared with that in group P, the volume of the prostate in group S was larger (50.21±27.03 ml vs. 45.01±28.26 ml, p <0.05).

2. **Causes of AUR**
The spontaneous AUR group (group S), which had no triggering events, included 160 patients (54%), and the precipitated AUR group (group P), in which AUR was consecutive to triggering events.

| Cause                        | Incidence |
|------------------------------|-----------|
| BPH natural history (spontaneous AUR) | 160 (54)  |
| Medications (parasympathomimetics, sympathomimetics, etc.) | 56 (18)   |
| Postoperative (with general or locoregional anesthesia) | 35 (12)   |
| Alcohol consumption | 24 (8)    |
| Urinary tract infections | 12 (4)    |
| Others (bed rest, urolithiasis, constipation, etc.) | 12 (4)    |

Values are presented as number (%). BPH, benign prostatic hyperplasia.

3. **Duration of catheterization and drained volume at catheterization**
The duration of catheterization and the drained volume at catheterization did not differ significantly between the groups (9.7±10.1 days vs. 8.9±9.1 days and 658.3±488.6 ml vs. 705.7±511.8 ml, respectively, p >0.05) (Table 3).
4. Treatment methods in each group

As shown in Table 4, compared with group P, patients in group S were more likely to be treated by surgery, either immediately (16.9% vs. 3.6%, p < 0.05) or after prolonged catheterization (42.2% vs. 29.1%, p < 0.05).

5. Success rate of TWOC

In group S, of the 135 men who underwent a TWOC, the trial was successful in 116 patients (87%), but 18 men (13%) had an indwelling catheter owing to voiding failure (Table 5). In group P, of the 134 men who underwent a TWOC, the trial was successful in 100 patients (74%), but 35 men (26%) had an indwelling catheter owing to voiding failure (Table 5). The success rate of TWOC was 74.1% in group S and 86.5% in group P. The presence of AUR-triggering factors increased the overall success rate of TWOC. Compared with group S, patients in group P were characterized by a smaller prostate (45.01±28.26 ml vs. 50.21±27.03 ml, p < 0.05) on transrectal ultrasound (TRUS) and a lower PSA level (5.32±6.13 ng/ml vs. 6.27±7.83 ng/ml, p < 0.05). The success rate of TWOC in patients with a drained volume at catheterization lasting ≥ 1,000 ml was lower than the success rate of TWOC in others (81% vs. 77%, p < 0.05). There was no significant difference between the success rate of TWOC in patients with a catheterization lasting ≥ 5 days and the success rate in others (81% vs. 77%, p > 0.05). The success rate of TWOC was lower in men of older ages (≥ 70 years) and with an enlarged prostate (≥ 50 ml), higher PSA (≥ 3 ng/ml), and large drained volume at catheterization (≥ 1,000 ml).

DISCUSSION

AUR is a common urological emergency in men and is defined as a sudden and painful inability to pass urine voluntarily. AUR represents the most common indication for BPH-related surgery, but its management is still not standardized because of a lack of existing guidelines [10]. Manikandan et al. [11] administered a questionnaire survey to 264 urologists in the United Kingdom on early treatments for BPH-caused AUR and reported that 98% of respondents used urethral catheterization and 70.5% used α-blockers concurrently with urethral catheterization.

Also, Taube and Gajraj [12] and Kumar et al. [13] reported in their studies that urethral catheterization was used as the initial treatment of AUR and that when patients were successful in self-voiding, the AUR recurred only in a small number of patients. They suggested that when patients with AUR have successful posturethral catheterization self-voiding, surgical treatment of BPH can be delayed or even avoided. A number of therapeutic options are available for AUR, ranging from medical therapy (usually α-blockers) to positioning of an indwelling catheter (or intermittent catheterization) and surgery. However, owing to the urgent nature of the problem and the need for fast and definitive treatment, immediate catheterization is often the first approach taken by urologists [14]. By analyzing clinical prognosis when urethral catheterization is used in patients with AUR, it will be possible to identify the appropriateness of TWOC as a primary treatment of AUR.

In this study, compared with the patients in group P, the patients in group S were more likely to be treated by surgery, either immediately or after prolonged catheterization. Furthermore, the success rate of TWOC was more than 70% for any type of AUR. TWOC is therefore recommended in the treatment of AUR.
those patients required either further catheterization or surgery. The size of the prostate is a known risk factor for AUR [2,15]. McNeill et al. [16] reported that when the size of the prostate is larger, AUR continues or has a high probability of requiring surgical treatment even after self-voiding has been achieved. When the size of prostate was rather small, they suggested that the AUR likely originated from other underlying causes, and in such cases, no surgical treatment is required. Daly et al. [17] reported that patients with elevated PSA (≥2.9 ng/ml), a large prostate size shown on a digital rectal examination (DRE), and a volume drained at the time of catheterization of >1,000 ml are best managed by surgical intervention, whereas patients with volumes drained at the time of catheterization of <1,000 ml, a PSA ≤2.9 ng/ml, and moderate to small prostates on a DRE may be managed medically. In this study, compared with the patients in group S, the patients in group P were characterized by a smaller prostate on TRUS and a lower PSA level. We analyzed the success rate of TWOC in the aspects of age, prostate size (TRUS), and PSA level regardless of type of AUR. Patients with AUR who were older than 70 years, had an enlarged prostate ≥50 ml, and had a higher PSA level (≥3 ng/ml) were shown to have a lower success rate of TWOC. In this study, we focused on the presence or absence of AUR-triggering factors regardless of the size of the prostate. Also, we identified that the presence of AUR-triggering factors increased the overall success rate of TWOC.

Taub and Gajraj [12] reported that when the urinary retention volume was ≥900 ml, it was highly probable that TWOC would fail in patients with AUR. Likewise, Djavan et al. [18] reported that when the urinary retention volume was ≤1,000 ml, there was likely a higher probability of self-voiding to succeed, whereas when urinary retention volume was >1,300 ml, the duration of catheterization should be extended. Fitzpatrick et al. [10] reported that a drained volume at catheterization of ≥1,000 ml influenced the success rate of TWOC, whereas catheterization for >3 days did not influence TWOC success but was associated with increased morbidity and prolonged hospitalization for adverse events. In the present study, the success rate of TWOC in patients with a drained volume at catheterization of ≥1,000 ml was lower than the success rate of TWOC in others. Patients with a catheterization time of ≥3 days were very small in number (n=28). Thus, we divided the patients into those with catheterization ≥5 days and those with catheterization <5 days. There was no significant difference in the success rate of TWOC in patients with catheterization ≥5 days and the success rate of TWOC in others.

BPH-induced AUR is considered to result by the sudden stimulation of the α1-adrenergic receptor that enhances contraction of the smooth muscle located between the prostate and the prostatic capsule, which leads to an increase in resistance of the bladder outlet [19,20]. Although it is known that α-blockers can delay BPH-induced AUR but cannot reduce the risk of cumulative incidence [21], several reports have suggested that the post-AUR use of α1-blockers prevents the recurrence of AUR and increases the success rate of self-voiding [9,18,22,23]. α1-Blockers are known to increase the maximal urinary flow and to reduce intravesical pressure, urethral opening pressure, and maximal intravesical pressure, thereby helping to start urination and its maintenance by lowering the intravesical pressure required for urination [24]. Fitzpatrick et al. [10] reported that most men (86%) received an α1-blocker (mainly alfuzosin) before catheter removal with consistently higher TWOC success rates, regardless of age and type of AUR, and multivariate regression analysis confirmed that the use of an α1-blocker before TWOC doubled the chances of success (odds ratio, 1.92; 95% confidence interval, 1.52 to 2.42; p < 0.001).

This study was conducted as a retrospective, multi-center study with various α1-blockers being used by each institution. Most of the patients’ records did not record the previous intake history of α1-blockers or the duration of such intake. Thus, we could not analyze the influence of α1-blocker use before TWOC on the success rate of TWOC.

The potential limitations of our study are as follows: 1) the subject number was insufficient because patients from a multi-center hospital participated in this study. 2) Because this study was a retrospective, multi-center study, we checked out the medical records of the patients but we could not get information on variables such as the history of use of α1-blockers before TWOC, symptoms of LUTS, etc. A further large-scale, prospective study is required to investigate the multiple factors that can influence the success rate of TWOC. Such a study will help to identify the predictors of successful TWOC. Also, the success rate of TWOC depending on the kinds of α-blockers used and previous intake history should be examined in further studies.

CONCLUSIONS

Among the AUR patients studied, the group with spontaneous AUR (54%) was somewhat larger than the group with precipitated AUR (46%). The success rate of TWOC was more than 70% regardless of the type of AUR. Although TWOC is recommended primarily in the treatment of AUR, early surgical intervention should be considered if a patient has an enlarged prostate (≥50 ml) or a large drained volume at the time of catheterization (≥1,000 ml).

CONFLICTS OF INTEREST

The authors have nothing to disclose.

REFERENCES

1. Kurita Y, Masuda H, Terada H, Suzuki K, Fujita K. Transition zone index as a risk factor for acute urinary retention in benign prostatic hyperplasia. Urology 1998;51:595-600.
2. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997;158:481-7.
3. Lepor H. The pathophysiology of lower urinary tract symptoms
Analysis of the Treatment of Two Types of Acute Urinary Retention

in the ageing male population. Br J Urol 1998;81 Suppl 1:29-33.
4. Mebust WK, Holmgren HE, Cockett AT, Peters PC. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 1989;141:243-7.
5. Murray K, Massey A, Feneley RC. Acute urinary retention: a urodynamich assessment. Br J Urol 1984;56:468-73.
6. Pickard R, Emberton M, Neal DE. The management of men with acute urinary retention. National Prostatectomy Audit Steering Group. Br J Urol 1998;81:712-20.
7. Emberton M, Fitzpatrick JM. The Reten-World survey of the management of acute urinary retention: preliminary results. BJU Int 2008;101 Suppl 3:27-32.
8. Cravens DD, Zweig S. Urinary catheter management. Am Fam Physician 2000;61:369-76.
9. McNeill SA, Hargreave TB; Members of the Alfaur Study Group. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. J Urol 2004;171(6 Pt 1):2316-20.
10. Fitzpatrick JM, Desgrandchamps F, Adjali K, Gomez Guerra L, Hong SJ, El Khalid S, et al. Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasia. BJU Int 2012;109:88-95.
11. Manikandan R, Srirangam SJ, O’Reilly PH, Collins GN. Management of acute urinary retention secondary to benign prostatic hyperplasia in the UK: a national survey. BJU Int 2004;93:84-8.
12. Taube M, Gajraj H. Trial without catheter following acute retention of urine. Br J Urol 1989;63:180-2.
13. Kumar V, Marr C, Bhuvangiri A, Irwin P. A prospective study of conservatively managed acute urinary retention: prostate size matters. BJU Int 2000;86:819-9.
14. Djavan B, Kazzazi A, Lepor H. BPH: Predicting TWOC failure in acute urinary retention. Nat Rev Urol 2012;9:181-2.
15. Hartung R. Do alpha-blockers prevent the occurrence of acute urinary retention? Eur Urol 2001;39 Suppl 6:13-8.
16. McNeill AS, Rizvi S, Byrne DJ. Prostate size influences the outcome after presenting with acute urinary retention. BJU Int 2004;94:559-62.
17. Daly P, Connolly S, Rogers E, Sweeney P. Management outcome of acute urinary retention: model of prediction. Urol Int 2009;83:39-43.
18. Djavan B, Shariat S, Omar M, Roehrborn CG, Marberger M. Does prolonged catheter drainage improve the chance of recovering voluntary voiding after acute urinary retention (AUR) [abstract]. Eur Urol 1998;33(Suppl 1):110. Abstract no. 437.
19. Alan McNeill S. The role of alpha-blockers in the management of acute urinary retention caused by benign prostatic obstruction. Eur Urol 2004;45:325-32.
20. Cockett AT, Khoury S, Aso Y, Chatelain C, Denis L, Griffiths K, et al., editors. Proceedings of the 3rd International Consultation on Benign Prostatic Hyperplasia (BPH); 1995 Jun 26-28; Monaco. Channel Island: Scientific Communications International Ltd; 1995. p. 1-651.
21. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98.
22. Annemans L, Cleemput I, Lamotte M, McNeill A, Hargreave T. The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysis. BJU Int 2005;96:566-71.
23. Shim JH, Sohng I, Jee KN, Kim HJ. Follow-up treatment of benign prostatic hyperplasia with acute urinary retention. Korean J Urol 2006;47:20-5.
24. Martorana G, Giberti C, Di Silverio F, von Heland M, Rigatti P, Colombo R, et al. Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia. Eur Urol 1997;32:47-53.